Seoul National University Bundang Hospital (SNUBH)
Glioma treatment cost in South Korea typically runs from AUD $35,596 to AUD $52,486 for a craniotomy, while essential diagnostics like a neurosurgeon consultation range from AUD $42 to AUD $140. Total expenses depend on the tumour stage, hospital tier, and whether you require advanced radiosurgery. Australians can expect to save between 30% and 50% compared to private healthcare costs in Australia or the United States. Key treatment hubs include Seoul and Seongnam.
Typical Glioma Treatment Costs in South Korea
Bookimed Expert Insight: For complex brain tumours, high-volume state facilities like Seoul National University Hospital offer the country's highest cancer treatment statistics. Patients needing advanced precision often choose Korea University Anam Hospital for its world-class robotic surgery skills and bloodless protocols. For safety, Seoul National University Bundang Hospital uses the digital BESTcare system to prevent medical errors during treatment. These JCI-accredited centres provide reliable alternatives when Australian waiting lists for specialist neuro-oncology are too long.
| Republic of Korea | Thailand | Turkey | |
| Gamma Knife | from AUD $18,845 | from AUD $34,898 | from AUD $6,002 |
| Craniotomy | from AUD $35,572 | from AUD $20,939 | from AUD $9,073 |
| Chemotherapy for breast cancer | from AUD $26,802 | from AUD $4,188 | from AUD $1,675 |
| Stereotaxic radiosurgery | - | from AUD $13,959 | from AUD $6,282 |
| Resection of glioma | - | - | from AUD $16,053 |
No hidden fees – just official clinic prices. Pay at the clinic for Glioma treatment and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Glioma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Glioma treatment journey.
South Korean neurosurgeons treat glioma using maximal safe resection supported by neuronavigation and intraoperative MRI. Standard protocols include the Stupp regimen for glioblastoma, combining concurrent radiation with temozolomide chemotherapy. Leading Seoul hospitals often hold JCI accreditation and follow international neuro-oncology guidelines for personalised care.
Bookimed Expert Insight: South Korea's oncology landscape is defined by extreme surgical volume, which often leads to higher proficiency. For example, Seoul National University Bundang Hospital performs over 32,500 operations annually. This high-volume environment allows neurosurgical teams to refine techniques. They include laparoscopic-assisted or digital-guided resections. These may be less common in lower-volume Australian centres.
Patient Consensus: Patients note that surgery is prioritised whenever the tumour is accessible. This helps reduce mass before starting six-week radiation courses. Experiences suggest that supportive care and symptom tracking help manage quality of life. This is vital during the managed temozolomide cycles in South Korea.
Foreign patients in the Republic of Korea receive support through International Health Care Centers at major hospitals. These units manage medical translations, coordination, and administrative needs. Facilities such as Seoul National University Hospital (SNUH) provide 24/7 interpreter services. Some centres also offer free airport transfers and dedicated personal coordinators.
Bookimed Expert Insight: While many patients focus only on medical stats, the scale of Korean university hospitals provides a safety net. Asan Medical Center and Severance Hospital each manage over 40,000 operations annually. This high volume means their international departments are exceptionally well-equipped. They handle complex billing and foreign insurance logistics without delays.
Patient Consensus: Patients note that Korean nurses do not provide bedside caregiving. However, large Seoul hospitals easily arrange private caregivers for around 150,000 KRW daily. Many suggest obtaining all diagnostic reports in English immediately. This simplifies follow-up care with specialists back in Australia.
Republic of Korea offers treatment for high-grade gliomas using precision neurosurgery and targeted radiation. Centres in Seoul frequently use Gamma Knife radiosurgery and Tomotherapy to treat complex brain tumours. JCI-accredited hospitals integrate molecular diagnostics to personalise chemotherapy and surgical plans for glioblastoma cases.
Bookimed Expert Insight: A trend in Korean neuro-oncology is the heavy investment in precision hardware. This includes Tomotherapy and Gamma Knife devices. For example, Gangnam Severance Hospital uses two Tomotherapy devices specifically for brain and spine cancers. This suggests a focus on highly accurate radiation delivery. Such accuracy helps reduce recovery times for international patients.
Patient Consensus: Patients find that Korean cancer care is often just as good as in the US. At the same time, it is more affordable. They specifically highlight the professional test setups and high standards at Severance Hospital. These strengths are particularly noted for complex oncology cases.
Clinical trials in South Korea provide vital access to experimental therapies. They often treat recurrent glioblastoma and high-grade gliomas. These studies test methods including focused ultrasound to bypass the blood-brain barrier and gene therapies. Major Seoul centres lead these trials under Joint Commission International (JCI) accreditation.
Bookimed Expert Insight: Data shows South Korean centres like SNUH and Asan Medical Center handle massive volumes. They perform over 50,000 surgeries annually. This high throughput allows these hospitals to run complex trials that require large patient cohorts. Australian patients should note that centres like Seoul National University Hospital offer 24/7 interpreter services. This support helps international participants navigate the complex consent and monitoring requirements. These are inherent in clinical trials.
Patient Consensus: Patients see trials as a primary way to access new drugs when standard care fails. These include CAR-T or Optune devices. They emphasise checking if a tumour matches specific molecular criteria. They also highlight that trials can help cover high treatment costs.
South Korean glioma treatment plans rely on multidisciplinary reviews and Korean Society for Neuro-Oncology guidelines. Teams of neurosurgeons, oncologists, and pathologists integrate molecular pathology with advanced imaging. They use maximal safe resection and targeted radiosurgery. At JCI-accredited centres like Severance Hospital, this approach helps individualise care.
Bookimed Expert Insight: The 'President's choice' for medical care often indicates the highest national standard. Seoul National University Hospital (SNUH) is where the South Korean President receives treatment. Its neurosurgery department performs 3,800 interventions yearly. For glioma patients, this volume correlates with refined surgical protocols. Gamma Knife technology, in particular, reports a 90% success rate at SNUH.
Patient Consensus: Patients note that the best plan involves balancing aggressive tumour removal with daily function. In South Korea, families value the sequence of surgery followed by chemotherapy. It is tailored specifically to the tumour’s molecular markers.
South Korean glioblastoma treatment offers a median survival of 15 to 19 months through multimodal care. Specialist centres achieve a 30% survival rate at 2 years using JCI-accredited protocols. Fluorescence-guided surgery and Gamma Knife technology help neurosurgeons maximise tumour removal. They also spare healthy brain tissue.
Bookimed Expert Insight: South Korea's high-volume neurosurgery centres like Gangnam Severance Hospital perform over 1,300 surgeries annually. This intense specialisation leads to faster access to care. For example, Korea University Anam Hospital offers same-day consultation and admission for new oncology cases. This speed is vital for aggressive tumours where every day matters for prognosis.
Patient Consensus: Patients note that while the disease is aggressive, surgery is worth it when tumours are operable. Individual results often vary from general survival averages. So families emphasise focusing on surgery quality and close monitoring in South Korea.
Glioma support in South Korea combines multidisciplinary clinical care with dedicated international services. Major centres provide neurosurgeons, oncologists, and radiation specialists who coordinate treatment plans. Patients access tools like Gamma Knife and Tomotherapy alongside 24/7 interpreter services at JCI-accredited facilities like Severance Hospital.
Bookimed Expert Insight: Patient volume data suggests a massive expertise gap in Seoul. Seoul National University Hospital treats 30,000 international patients annually and conducts 3,800 neurosurgical procedures. This high volume allows teams to manage complex glioma cases that smaller regional centres rarely see. Australian patients should focus on these high-capacity university hospitals for better access to specialised neuro-oncology teams.
Patient Consensus: Patients emphasise the need for multidisciplinary teams covering rehab and palliative care to manage daily function. They also recommend securing full pathology reports early. This facilitates second opinions during the treatment process in South Korea.